alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
about
C-galactosylceramide: Synthesis and immunologyGlycolipid transfer proteinsCD1d- and MR1-Restricted T Cells in SepsisAntitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cellsStructural Evaluation of Potent NKT Cell Agonists: Implications for Design of Novel Stimulatory LigandsStructural and Functional Characterization of a Novel Nonglycosidic Type I NKT Agonist with Immunomodulatory PropertiesInvariant natural killer T cells and their ligands: focus on multiple sclerosisNatural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitisIL-15 regulates homeostasis and terminal maturation of NKT cellsAlpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha 14 invariant natural killer T cells to negatively regulate gammadeltaT cells.Invariant NKT cells sustain specific B cell responses and memory.PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cellsThe 3-Deoxy Analogue of α-GalCer: Disclosing the Role of the 4-Hydroxyl Group for CD1d-Mediated NKT Cell Activation.Stimulation of natural killer T cells by glycolipidsInvariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette.Heteroaromatic Moieties in the Sphingosine Backbone of α-Galactosylceramides for Noncovalent Interactions with CD1dLipid and glycolipid antigens of CD1d-restricted natural killer T cells.Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.Natural killer T cell sensitization during neonatal respiratory syncytial virus infection induces eosinophilic lung disease in re-infected adult miceGlycolipid antigen induces long-term natural killer T cell anergy in mice.Synthesis of immunostimulatory alpha-C-galactosylceramide glycolipids via Sonogashira coupling, asymmetric epoxidation, and trichloroacetimidate-mediated epoxide opening.Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.Role of sphingolipids in microbial pathogenesisThe ROS scavenger, NAC, regulates hepatic Vα14iNKT cells signaling during Fas mAb-dependent fulminant liver failure.Presentation of lipid antigens by CD1 glycoproteins.Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.Anti-inflammatory effects of α-galactosylceramide analogs in activated microglia: involvement of the p38 MAPK signaling pathway.Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay.CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injuryImmune modulating effects of NKT cells in a physiologically low dose Leishmania major infection model after αGalCer analog PBS57 stimulationDeficiencies of Circulating Mucosal-associated Invariant T Cells and Natural Killer T Cells in Patients with Acute CholecystitisSynthesis and Biological Activities of 5-Thio-α-GalCers.The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their ProductsBorder Patrol Gone Awry: Lung NKT Cell Activation by Francisella tularensis Exacerbates Tularemia-Like DiseaseStage-dependent reactivity of thymocytes to self-peptide--MHC complexes.Cell therapy for autoimmune diseasesA novel role for NKT cells in cutaneous wound repairDesign, Synthesis, and Immunological Evaluation of Benzyloxyalkyl-Substituted 1,2,3-Triazolyl α-GalCer Analogues.An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
P2860
Q24625835-B7F1FCB8-AB68-465A-BFA6-F87CA196BE61Q24682530-C6B8CF2B-74E9-404D-823C-C95BA8CC2888Q26796132-EAAE1B1F-0949-474A-B8EE-5DF98F16C3E3Q27003110-1C4F3B22-54CB-40A5-BB9C-6629AA0AFE69Q27657337-2AE01657-812F-4A62-899B-EECC34F4DB06Q27677017-8CA1E03C-D13E-4C17-A248-FBBFCA127B72Q28083069-308DCBC1-0422-446B-964D-B3EDB2F9D76DQ28085038-91B718C4-DBA8-4E19-BA45-33BC20AE2DB7Q28741430-B20D657F-E5E0-4634-A1AB-142A5BCA79DEQ30377447-477A7A8F-20C3-40C7-917E-CFFBBE826E5BQ30432794-F1715A83-EA7E-4D62-AC17-8576CB21D466Q30479030-01886330-59DA-4C86-B8D6-20E87A8FC7C3Q30488777-8E24F352-9596-430D-BB0C-2266D91E8841Q33598825-5C382280-F107-45E8-966A-80FAAB87C7E5Q33599059-45E85CBF-809E-4338-A784-727622A3A088Q33604484-7C7D20AB-84E5-4CD3-8F27-62CE4622EC57Q33630528-D4841E65-0D42-4395-89E5-1CFBF297BD30Q33724575-EA0FCEBC-089B-4959-9D04-6733B2851D93Q33733648-A6707E73-7BFE-4156-8F9A-DB0F7D0BE134Q33751615-A40FA1F6-7D01-4840-8D3C-A7E4E1EFEC51Q33930869-25637701-CDE3-4C59-A694-58C514E4E7B4Q33959266-40E97076-8701-4299-A07D-5BE891F484AFQ34172161-D141EB0C-F963-42C4-BDB1-5710368DDAFDQ34300991-2767B878-99E0-46F3-ADEF-558A2843698BQ34305284-1A9F4C3A-7174-41B3-A637-CCC6D954F1BAQ34987421-B6A08284-4189-457D-AECE-798A0B0F9A2CQ35071875-32B593A5-8516-42E6-BE3F-9B4EAC9A5B37Q35093530-0BDAB707-17E4-43F6-BD85-CF86CBA06B0EQ35102253-66641F6E-26CA-4591-A8A1-58E914B8E8E0Q35139286-945B6C67-372F-40BD-9712-5136283C0F06Q35195426-8B855D20-278D-4AAC-9675-3C3A1385958DQ35553709-51CAB31A-861E-46B1-8143-DE8FCC48CAD5Q35559790-C03C1A23-E0BE-4D49-94CF-09493DF01D1BQ35600087-4BB1C601-0ABA-407A-95D3-232FE31A6959Q35661972-80C58984-E7FA-4FBE-B0AF-D98A692A6D59Q35691052-9461D77C-62AA-4B90-893A-75923EA46D01Q35868954-D68FEDE4-8B8D-4AD2-B306-B26D045E2C11Q35885094-532F19C1-05FE-4EA2-A151-16A21A348E41Q35960321-25C8EDD5-433A-465B-BE8F-6A78A8E73E94Q35990678-80757929-502A-4D36-9D64-FBA278673DEB
P2860
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@ast
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@en
type
label
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@ast
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@en
prefLabel
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@ast
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@en
P2860
P356
P1476
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
@en
P2860
P356
10.1038/NRI1531
P50
P577
2005-01-01T00:00:00Z